Serial No. 09/424,091

Filed: February 23, 2000

Title: Immunological Metho

Applicant(s): Richard Andre Group Art Unit No. 1644

Examiner: Amy M DeClou

## **CERTIFICATE OF MAILING**

certify that on April 9, 2002, this paper (along with any paper referred to as being Tattached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the U.S. Patent and Trademark Office, BOX SEQUENCE, P.O. Box 2327, Arlington, VA 22202

37 CFR 1.8(a) with sufficient postage as first class mail

37 CFR 1.10 ☐ as "Express Mail Post Office to Addressee" Mailing Label

Florence Thys-Douce (Type or print name of person mailing paper)

(Signature of person mailing paper

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Patent and Trademark Office Box sequence, P.O. Box 2327 Arlington, VA 22202

> SUBMISSION OF SEQUENCE LISTING, COMPUTER READABLE COPY AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE (37 CFR §§ 1.821-1.825)

Dear Ms. DeCloux:

Responsive to the Notice to Comply, mailed March 28, 2002, Applicant enclose herewith a copy of the SEQUENCE LISTING in computer readable (ASCII) form and as an MS Word document. A paper copy of the SEQUENCE LISTING in compliance with 37 CFR §§ 1.821-1.825 for the nucleotide and amino acid sequences disclosed in the above-referenced application is also submitted herewith.

> STATEMENT THAT COMPUTER READABLE COPY OF THE SUBSTITUTE SEQUENCE LISTING IS THE SAME AS THE PAPER COPY OF THE SUBSTITUTE SEQUENCE LISTING

## I hereby state:

1. The computer readable (ASCII) form and the MS Word document of the SUBSTITUTE SEQUENCE LISTING submitted in this application is the same as the paper copy of the SUBSTITUTE SEQUENCE LISTING to which it is indicated to relate.

2. All papers accompanying this submission introduce no new matter to the accompanying application.

## **VERIFICATION**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of the Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

The Commissioner is hereby authorized to charge any additional filing fees under 37 C.F.R. § 1.16, or application processing fees under 37 C.F.R. § 1.17, which may be required now or during the pendency of this application, or credit any overpayment to Account No. 16-2230.

Respectfully submitted,

Dated: April 9, 2002

Guy Porter Smith, Reg. No. 20,142

**OPPENHEIMER WOLFF & DONNELLY LLP** 

2029 Century Park East, Suite 3800

Los Angeles, California 90067

(310) 788-5000